Dive into the latest research on #RA with our new in-depth slide decks and literature highlights! Available now for free on the #IMIDForum: imidforum.com/literature-rev…
27
This month on our author interview, Professor Peter Nash and Doctor André Lucas Ribeiro describe the patient profiles, treatment patterns, clinical outcomes, and safety of intentional dual b/tsDMARD therapy in PsA.
Catch this insightful discussion on the #IMIDForum: imidforum.com/podcasts/episo…
47
👉 Our November literature search identified 7 new papers in #AxSpA!
👀 View the results by clicking the link below: imidforum.com/resources
47
👉 Our November literature search identified 15 new papers in #PsA!
👀 View the results by clicking the link below: imidforum.com/resources
31
Stay informed with our latest #RA literature highlights and detailed slide decks. Now available for free on the #IMIDForum: imidforum.com/publications
32
Check out our newest #PsA author interview 🎬 featuring Professor Peter Nash and Doctor André Lucas Ribeiro over on the #IMIDForum website: imidforum.com/podcasts/episo…
44
Ibis et al. reported that among adults aged ≥75 years with RA, JAK inhibitor initiation was not associated with significantly higher risks of MACE, VTE, malignancy or mortality compared with TNFi(s) over 3 years. imidforum.com/publications/9… #IMIDForum
36
Russell et al. reported higher remission rates with initial b/tsDMARDs plus MTX than with MTX alone, with benefits evident from 3 months.
imidforum.com/publications/9… #IMIDForum
41
What about cell-directed therapies as a completely new way of treating axial spondyloarthritis in future? Let's hear from Professor Atul Deodhar regarding a new discovery at #ACR2026!
Leave a comment below to share your thoughts or questions about this innovative approach ⬇️⬇️
🌟 Highlighted 🌟
9:45am-10:00am
2942: Ixekizumab Plus Tirzepatide Demonstrated Greater Disease Control at 52 Weeks Versus Ixekizumab Alone With Incremental Improvement From Week 36 in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomised Clinical Trial
Joseph Merola, MD, MSc, FACR, FAAD
#ACR2026
1
59
Merola et al. reported that IXE+TZP showed benefit in disease activity as early as Week 4. Results from TOGETHER-PsA provide longer-term data supporting the concomitant use of IXE and TZP to
manage PsA as an immunometabolic disease, with potential to improve disease control, QoL, cardiometabolic outcomes, and overall health #PsA
55
🌟 Highlighted 🌟
8:30am-8:45am
LB21: TARA: A Phase 3 Head-to-Head Trial of Girocitinib vs Tofacitinib in Patients with Active Rheumatoid Arthritis Refractory to bDMARDs
Xiaofeng Zeng, MD
#ACR2026
1
84
Final day! 📅
Our Day 4 Daily Highlights podcast for ACR is here!
Tune in now to hear from IMID Steering Committee member, Dr Sofia Ramiro, as she runs through all of the highlights for the 11th November.
Listen here! 🎧 imidforum.com/congress/88/ac…
38
Professor Kevin Winthrop gives us an insight into his keynote opening address at the Global Rheumatology Summit here at #ACR2026 ➡️🎬
👉 Our November literature search identified 10 new papers in #IBD!
👀 View the results by clicking the link below: ow.ly/2jQG50ZNlF7
29
👉 Our November literature search identified 69 new papers in #PsO!
👀 View the results by clicking the link below: imidforum.com/resources
40
🌟 Highlighted 🌟
4:15pm-4:30pm
2904: Long-Term Safety of Upadacitinib in Clinical Trial and Clinical Practice Settings: Risk of Infection, Malignancy, Cardiovascular Events, and Thromboembolism in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis
Gerd Burmester, MD, MACR 👤
#ACR2026
55
We caught up with our IMID Rheumatology Steering Committee member Professor Johannes Bijlsma, as he summarises the year-in-review session on Day 1 of #ACR2026 🌎
🌟 Highlighted 🌟
2:00pm-2:15pm
2879: Evaluation of the Modified Berlin Algorithm for Diagnosing Axial SpA in Patients with Chronic Back Pain: Data from the SPondyloArthritis Caught Early (SPACE) Cohort
Liese de Bruin, MSc 👤
#ACR2026










